Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update

FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality...

Related Keywords

United States ,New Jersey ,Bedminster ,American ,Jody Cain ,Matinas Biopharma ,Jeromed Jabbour ,National Resilience Inc ,National Resilience ,Development Authority ,Access Program ,European Congress ,Matina Compassionate Expanded Use Program ,Drug Administration ,Population Pathway For Antifungals ,Oral Amphotericinb Program ,Key Program Updates ,Matinas Biopharma Holdings Inc ,Company Compassionate Expanded Use Access Program ,Small Oligonucleotide Program ,Biomedical Research ,Compassionate Use Program ,Expanded Use Program ,Nationwide Children ,Chief Executive Officer ,Limited Population Pathway ,Expanded Use Access Program ,Clinical Microbiology ,Infectious Disease ,Expanded Access Program ,Eunkyung Song ,Private Securities Litigation Reform Act ,Biopharma Holdings ,Consolidated Statements ,Markets ,